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ABSTRACT 
Microbubbles and nanodroplets are tools used in medicine for diagnosis and therapy. 
Probubbles are initially submicrometer droplets that become microbubbles in tumors as a 
result of ultrasonic force. The aim of this investigation was to determine vaporization 
thresholds of perfluorocarbon (PFC) droplets as a function of PFC boiling point and 
droplet size. PFC droplets with boiling points -1. 7 to 56.6°C were formulated followed 
by acoustic droplet vaporization (ADV) and stability testing. Under ultrasound acoustic 
outputs used, perfluorohexane (PFH) droplets did not vaporize while perfluoro(-2-
methyl-3-pentanone) (PFMP), perfluoropentane (PFP), and perfluorobutane (PFB) 
droplets did vaporize. The acoustic output required to vaporize droplets decreased with 
decreasing boiling point. Vaporization threshold is a function of size with larger diameter 
droplets requiring less ultrasound output to vaporize. PFH, PFMP, and PFP droplets 
remained stable after 16 weeks in 4°C and 23°C environments, but PFMP and PFP 
evaporated entirely in a 40°C oven after 12 weeks. 
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1. INTRODUCTION AND LITERATURE REVIEW: DESIGN RATIONALE 
According to the latest SEER (Surveillance Epidemiology and End Results) report 
from the National Cancer Institute, it is estimated that 1.5 million people were diagnosed 
as having cancer in 2010 in the United States (Alekruse, et al., 2009). Cancer is the 
uncontrolled growth of cells in terms of size and duplication where apoptosis 
(programmed cell death) is no longer in existence for such cells. As a result of 
uncontrolled growth, cancer cells oftentimes have the ability to spread to other areas of 
the body affecting other normal tissues in a process referred to as metastasis. 
Uncontrolled cell growth can also result in large masses of abnormal tissue known as 
tumors or neoplasms (Sticker and Kumar 2003). There are essentially two types of 
tumors, benign and malignant, for which four primary features can generally distinguish 
them: I) differentiation and anaplasia: 2) rate of growth: 3) local invasion: and, 4) 
metastasis (Sticker and Kumar 2003 ). Tumors tend to promote angiogenesis resulting in 
being surrounded by "leaky vasculature" where the endothelial gap junctions are not as 
tight compared to areas where no tumor is present. Thus, the vasculature around a tumor 
is rather disorganized, distributed unevenly, and dependent on cell survival factors such 
as vascular endothelial growth factor (VEGF) in order to remain viable (Jain and Duda 
2008). Such characteristics can be used as key markers in order to help detect and treat 
cancer. 
Early detection and removal has been proposed as one of the methods to get rid of 
cancer especially prior to metastasis. There are biomarkers that can be identified in order 
to help identify cancer, a biomarker being any biological indicator that can be associated 
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with characteristics of tissue function. Some examples of biomarkers for some 
pathologies include changes in blood flow, blood perfusion, electrical activity, 
temperature, and pressure. In addition, there are many biomarkers for detecting early 
stage cancers, but few possess sufficient specificity and sensitivity needed for early stage 
detection. Even so, some methods of detecting cancer include detecting various 
biomarkers through blood chemistries, biopsies, and/or through the use of various 
imaging modalities such as computed tomography (CT), single photon emission 
computed tomography (SPECT), positron emission tomography (PET), optical imaging, 
magnetic resonance imaging (MRI), and ultrasound. An example of a biochemical 
biomarker includes prostate specific antigen (PSA) that can be detected via blood tests 
(Sticker and Kumar 2003). Biopsies (tissue samples) of cancer fixed onto microscope 
slides with stains such as hematoxylin and eosin are still a standard methodology for 
detecting abnormal cellular features mentioned earlier. Lastly, although imaging 
modalities alone could potentially detect some cancers, their effectiveness in terms of 
quality may be hindered by the non-specificity and lack of sufficient sensitivity of their 
imaging capabilities. Clearly, imaging can definitely be improved. 
In order to enhance cancer cell imaging, contrast agents are usually necessary. For 
example, ultrasound imaging provides suboptimal images for echocardiography. 
Oftentimes, B-mode ultrasound offers equivocal information with regards to ventricular 
border definition and ventricular chamber delineation, and it offers no information 
regarding myocardial blood flow. Similar limitations can be seen for imaging the liver, 
kidney, and tissue. Today, microbubbles are common chemical contrast agents used to 
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enhance the suboptimal images by changing the acoustic impedance, which provides 
higher contrast and delineation of heart tissue (Section 1.1 has more details about this 
phenomenon). Furthermore, microbubbles can be used in conjunction with newer 
ultrasound pulse sequences to provide valuable information about myocardial and tissue 
blood supply as well as increased highlighting of tumor tissue. 
Each imaging modality has advantages and disadvantages. In general, CT, SPECT, 
PET, optical imaging, and MRI scans can provide images of almost anything including 
bone and gas. However, CT, SPECT, PET, and MRI scans require patients to remain still 
making them less convenient. In addition, CT and SPECT machines are relatively 
expensive and require ionizing radiation that could potentially be mutagenic (Prince and 
Links 2006). Nonetheless, one of the most cost effective, safest, popular, and portable 
imaging modalities is ultrasound, which is not as invasive and is essentially risk free if 
used with clinically acceptable acoustic outputs (Prince and Links 2006). Ultrasound 
imaging is especially good for evaluation of pain and swelling, examining internal 
organs, and guiding biopsies because it exploits the advantages of non-invasiveness, 
convenience, and real-time imaging while avoiding or minimizing disadvantages of 
ionizing radiation, needles, and cost. Table 1.1 below displays the imaging modalities 
discussed and their corresponding sensitivities of usable concentrations of contrast agents 
per imaging modality. 
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Table 1.1. Imaging modalities and spatial resolution (1Massoud and Gambhir 2003, 2Thomsen 2009, 
3 4 Blod ~ett 2010, Un~er, et al., 2003). 
Imaging Contrast Agent Dose Duration1 Clinical Spatial 
Modality Sensitivity (M) 1 Resolution 
(mm)1 
CT Iodine2 10-3 minutes 0.05-0.2 
SPECT lodine 1 10-10_10-11 minutes 1-2 
PET lXF FDG3 10-11_10-12 10 sec to 1-2 
minutes 
MRI Gadolinium- 10-3-10-5 minutes to 0.025-0.1 
based2 hours 
Ultrasound Perfluorocarbon 10-4- 10-5 seconds to 0.05-0.5 
(5 MHz) microbubble4 minutes 
Ultrasound uses a transducer to induce pressure sound waves, which are 
subsequently detected after reflecting off of objects (individual tissues interact in 
differential ways with sound) in order to create an image of a localized region of tissue. 
A piezoelectric transducer induces set frequencies (MHz) and power (W/cm2), which 
creates the pressure waves in addition to receiving reflective sound energy from the areas 
of interest (Prince and Links 2006). The US Food and Drug Administration (FDA) has 
indicated the Mechanical Index (Ml) (Equation 1) as an important ultrasound parameter 
because of the desire to prevent potential bioeffects (Section 1.5). Typical mechanical 
indices in clinical settings range from 0.05 to an FDA approved maximum of 1.9. 
1.1. Vascular Contrast Agents 
MI= {l 
where Pr : peak negative pressure (MPa) 
f: center frequency (MHz) 
Equation 1 
In general, vascular contrast agents are i11jected intravenously (i.v.) into the 
vascular space in order to help provide better contrast when imaging the cardiovascular 
15 
system. Vascular contrast agents can be used for numerous applications including direct 
diagnoses and treatments. Various imaging modalities have their own corresponding 
contrast agents. Each contrast agent alters the energy (absorption, relaxation, reflection, 
or emission) provided by the imaging modality, which thereby provides contrast in order 
to assist physicians in visualizing a region of interest (ROI). For example, the vascular 
contrast agents for CT have generally been iodine-based where the x-ray beams become 
weakened and contrast increases. The vascular contrast agents for MRI have been 
gadolinium-based, which shorten the relaxation times of hydrogen nuclei of water 
molecules. Most of the vascular contrast agents for ultrasound are microbubbles 
although there has been some interest in echogenic liposomes (ELIPS) as well (Alkan-
Onyuksel, et al., 1996). 
Microbubbles are primarily lipid-coated bubbles that are used as ultrasound contrast 
agents and are filled with air, perfluorocarbon gas, or sulfur hexafluoride. Furthermore, 
the gas solubility properties of the gases in the aqueous milieu are one component that 
determines their circulating lifetime. Other factors include microbubble size (smaller size 
results in less susceptibility to elimination via the reticuloendothelial system [RES]) and 
lipid composition (microbubble membranes with polyethylene glycol [PEG] offer 
"stealth" qualities so as to not be recognized by the RES). The gases used in 
microbubbles work by increasing the backscattered echoes at the gas-water interface 
(impedance mismatch) during ultrasonic imaging. The first reported use of a 
microbubble was in 1968 when Gramiak and Shah injected air bubbles produced by 
quick injection of saline into the aortic root (Gramiak and Shah 1968). From there, the 
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field of ultrasound contrast agents gained interest, and now, there are several ultrasound 
contrasts agents on the market for clinical use. Most of the ultrasound contrast agents are 
microbubbles that are injected i.v. and assist in ultrasonography by exhibiting a different 
reflection of sound energy ( change in acoustic impedance at the gas-liquid interface) 
while providing high contrast and delineation of diseased tissues within the 
cardiovascular system. 
~ ~ PEG 
PFC/Oil 
_ _ Drug 
Figure 1.1. Microbubble with lipid shell and gaseous perfluorocarbon (PFC) core. Polyethylene 
glycol (PEG) tail is used for stealtb and potential ligand attachment for cell specificity, and oil is used 
to help internalize and stabilize a potential drug. 
According to Albers in 1960, the backscatter of a bubble in the Rayleigh scattering 
regime is related to the sixth power of the bubble radius, which suggests that large 
decreases in backscatter can occur with slight decreases in bubble radius (as cited in Wei, 
et al., 1998). Specifically, the contrast is due to an occurrence known as Rayleigh 
scattering. Rayleigh scattering occurs especially with microbubbles because of their 
extreme difference in acoustic impedance compared to blood and tissue. This impedance 
also causes a difference in backscattering of ultrasound that results in visibility even at 
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low mechanical indices. If the particles (microbubbles) are much larger causmg 
backscattering of ultrasound at higher angles, then the type of scattering is referred to as 
Mie scattering. Both are the theories involved that help explain the mechanism behind 
the contrast shown in ultrasound images provided by microbubbles. 
Despite their utility as vascular contrast agents, one of the limiting factors of 
micro bubbles is their diameter ( ~ 1-5 µm), which limits their use to the intravascular 
space. As mentioned earlier, larger microbubbles provide more contrast via ultrasound 
imaging, but the size must be limited to a maximum diameter to allow unobstructed flow 
through the capillaries. Alternatively, even 1 µm diameter bubbles may be too large for 
extravasation outside "leaky" vasculature according to one study, which has founded that 
780 nm diameter particles may be the largest to passively diffuse into the tumor site 
(Hobbs, et al., 1998). However, there is no specified size threshold that can be defined 
with passive diffusion through "leaky" vasculature because it is dependent on numerous 
factors including the stage of the tumor, the number of micro bubbles involved, and how 
much time is necessary to allow for microbubbles to accumulate within or near the tumor 
site. Therefore, it is important to identify that it is currently unknown as to what ideal 
size would be necessary in order to passively diffuse to the extravascular space for any 
tumor. Also, although one 1 µm diameter microbubble is sufficient to be detected on the 
ultrasound image, a plethora of microbubbles cannot passively extravasate to. the 
extravascular space and an alternative design approach may be needed. 
1.2. Perjluorocarbons 
Typically, perfluorocarbons (PFCs) have been used as the primary gas for vascular 
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contrast agents because they are essentially inert and will not be converted with any 
human metabolic function (Spahn, et al., 1994 and Keipert 1998). Not being metabolized 
presents an advantage when used as an imaging tool as it will eventually become excreted 
unchanged through the lungs over time. Even though perfluorocarbons are amphiphobic 
( dislike nearly everything), their stability in microbubbles is due to: 1) their virtual 
insolubility in water, and 2) their encapsulation in a shell. Furthermore, their elastic 
properties also enhance their echogenicity, which in tum provides better contrast during 
ultrasonic imaging. Nonetheless, they still need to be encapsulated by either polymeric 
shells or surfactants to reduce the interfacial tension between water and perfluorocarbons. 
The reduction in surface tension results in a reduction in Laplace pressure, which assists 
in stabilizing bubbles, especially the smaller ones. Laplace pressure is the difference 
between the pressure inside of a droplet/bubble and the pressure outside of a 
droplet/bubble. A surfactant such as a lipid coating would not only be necessary to 
encapsulate perfluorocarbons but also to stabilize lower boiling perfluorocarbons in order 
to prevent from them vaporizing too soon. 
The membrane coating of encapsulated perfluorocarbons could vary depending on 
the contents and phases of the internal core and surrounding environments. Most 
perfluorocarbon bubbles tend to be comprised of a lipid monolayer membrane, so they 
could conceivably be referred to as gas-filled micelles (Singha!, et al., 1993). Liposomes 
typically have lipid bilayers similar to cellular structures with polar heads facing inwards 
and outwards because the aqueous milieu is both internal and external. The 
perfluorocarbon emulsions (droplets) tend to involve a monolayer even though 
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perfluorocarbons are amphiphobic. 
I. 3. Requirements for Vascular Diffusion 
In order to extravasate out of the vasculature and passively diffuse to an area of 
disease or tumor, microbubbles must either have small diameters (hundreds of nm) or 
begin as a smaller particle such as a droplet (also hundreds of nm). Typically, the 
vasculature near an area of disease or tumor is "leaky" such that the spacing of the 
endothelial gaps is larger than normal. Another term for this characteristic is increased 
vascular permeability. Some studies suggest that the lengths of the intercellular 
endothelial gaps of "leaky" vasculature can be as small as 30 nm and as large as 780 nm 
(Mayer, et al., 2002; Hobbs, et al., 1998) although these still have not been defined and 
are dependent on the stage of the tumor. Thus, the vasculature for tumors remains 
permeable due to several factors such as vascular endothelial growth factor (VEGF), 
bradykinin (BK), and nitric oxide (NO) to maintain pathways for nutrients for the tumor 
cells (Maeda, et al., 1994). Along with the permeability factors, it appears that 
macromolecules and lipids accumulate in tumor tissue and remain for long time periods 
(Matsumura and Maeda, 1986). This characteristic is commonly referred to as the 
enhanced permeability and retention (EPR) effect (Matsumura and Maeda, 1986). It is 
the EPR effect near tumor sites that many scientists would like to exploit, especially with 
regards to cancer therapeutics. Therefore, several devices have been developed in an 
effort to help diagnose and treat cancer including microbubbles and emulsion droplets. 
1.4. Requirements for Ultrasound-Mediated Vaporization 
In general, droplets are defined as bodies of liquid suspended within another liquid. 
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Frequently, droplets are created via emulsion chemistry with two immiscible liquids such 
as either oil-in-water or water-in-oil, and they form because of the interfacial tension that 
exists between the two liquids (McClements, 2005). In this case, droplets are typically 
smaller than microbubbles having diameters < 1 µm and they contain a perfluorocarbon 
liquid core rather than a gaseous core. However, it is possible to make droplets to have 
diameters in the micrometer range as well. As microbubbles are typically restricted to 
the vasculature due to their size, droplets that have hundred nanometer diameters are 
capable of passively diffusing through the intercellular endothelial gap junctions and into 
the extravascular space (Dayton, et al., 2006). Because of their ability to move beyond 
the extravascular space, their potential application as therapeutic drug deliverers and 
imaging agents is further expanded. 
1.5. Potential.Bioeffects 
No imaging modality, including ultrasound, is one hundred percent safe, and there 
are potential bioeffects. Bioeffects can occur as a result of an imaging device affecting 
normal cells and tissues that cause abnormalities over time. The goal of my project was 
to design a droplet that can undergo non-inertial cavitation into a microbubble using a 
low MI as this lowers the probability of having bioeffects. Ultrasound alone provides 
both thermal and mechanical energy that can be transferred to cells. The amount of 
energy can increase the temperature in cells that can eventually be damaging. The 
thermal index (TI) represents the amount of heat energy applied to tissues (Equation 2) 
and has been used concurrently with the MI to monitor applications of ultrasound energy. 
Although the MI remains as the primary indicator currently used on most ultrasound 
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machines, the MI might not be the best indicator of ultrasound energy because there 
appears to be no direct relationship between MI and microbubble cavitation (Forsberg, et 
al., 2005). 
w Tl= -- Equation 2 
Wdeg 
where W: total acoustic power 
W deg: acoustic power required 
to raise the temperature of tissue 1 °C 
Some bioeffects may include a number of abnormal biological alterations to 
molecular and/or cellular structures. Heating causes bioeffects by increasing the 
temperature higher than the normal physiological temperature. Reports of consequences 
from heating mainly involve embryonic development in animals (Barnet, et al., 1997, 
Barnett, et al., 2000, and Ziskin 1999). In addition, heating can promote inflammation 
(Speed 200 I), wound repair (Speed 2001 and Jackson, et al., 1991 ), and production of 
heat shock proteins (Barnett, et al., 1990 and Walsh, et al., 1987). Most reports of 
bioeffects from cavitation refer to inertial cavitation of microbubbles where the 
microbubbles are disrupted. The bioeffects from cavitation are stimulations of 
arteriogenesis and angiogenesis (Song, et al., 2002, Song, et al., 2004, and Skyba, et al., 
1998). More importantly, cavitation of micro bubbles after application of ultrasound can 
rupture the surrounding endothelial membrane (Skyba, et al., 1998). Therefore, it is 
important that the probubble design can undergo non-inertial (stable) cavitation and 
inertial cavitation under conditions that will be as minimally damaging as possible. 
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1. 6. Design Proposal 
We propose that a probubble can be designed to act as a potential diagnostic 
and/or therapeutic tool. The probubble is initially a droplet that contains a lipid shell with 
a liquid perfluorocarbon core and is small enough to passively diffuse into the 
extravascular space, especially near a tumor site. A polyethylene glycol tail can be 
attached to the lipid pointing outwards for stealth and to allow for potential attachment of 
a ligand that would be specific to the particular target cancer cell. The droplet will then 
attach to the receptor of the target cell. Furthermore, uptake enhancers such as folic acid 
may also be incorporated onto the droplet surface to enhance internalization. Once the 
droplet has been internalized into the target cell (after 1-2 days to allow for circulation, 
EPR effect, and physiological washout), an ultrasonic pulse will provide thermal and 
mechanical energy specific for the droplet in order to induce non-inertial cavitation of the 
droplet into a microbubble, which will cause the liquid core to become a gas core 
resulting in expansion of the droplet into a microbubble. Thus, the microbubble will not 
be disrupted and remain stable for the duration of ultrasound imaging. 
PFC Liquid Core 
..... 
L1p1d~•■••. , 
• I • 
• . I 
-.;.;.•· 
PFC Gas Core 
Figure 1.2. Probubble design in initial and final states. Initial state is on left indicative of 
perfluorocarbon-filled droplet due to liquid core and smaller diameter. Final state is on right 
indicative of perfluorocarbon microbubble due to gaseous core and larger diameter (approximately S 
times greater than droplet diameter). Probubble contains lipid shell for added stability with 
polyethylene glycol (PEG) tails for potential ligand attachment. Conversion from droplet to 
microbubble will occur after application of ultrasound energy . 
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Once the gas core results in at least a 1 µm in diameter microbubble, the ability to 
view the microbubble via ultrasonic imaging is feasible, revealing the location of the 
target cell if the ligand-receptor moiety is target-specific and not found in normal cells. 
This may help diagnose several different types of diseases much less invasively than 
other procedures such as biopsies, and this should also be a cheaper alternative than CT 
and MRI. As far as therapeutic applications, once the microbubble is visible in the 
ultrasound display, an increase in MI should allow further inertial cavitation of the 
microbubble (Holland and Apfel 1990) into a larger volume to occupy space of the target 
cell eventually destroying only the target cells as the microbubble collapses (Figure 1.3). 
However, numerous microbubbles must be internalized in one target cell for ablation 
because the cells are at least 10 µm in diameter. Alternatively, the microbubbles 
themselves can potentially serve as toxins to the tumors cells depriving them of 
nourishment and preventing further growth. 
However, it is necessary to learn more about these droplets and determine if they 
are able to perform each sequence in the probubble application. Here, we want to address 
the following: 1) vaporization as a function of average diameter, 2) vaporization as a 
function of boiling point, and 3) stability of droplets. Although some generalizations can 
be made about the membranes of the droplets being monolayer, bilayer or multilayer, the 
formulation here is somewhat different from other droplets. Therefore, some 
assumptions will be made about these droplets. For example, the droplets are essentially 
emulsions and will be assumed to take on spherical structures. In addition, it will be 
assumed that the droplets can be reproduced with uniform size (see Section 2.1 ). 
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Primarily, it is important to identify the vaporization thresholds of these droplets as a 
function of size and boiling point. Secondly, the storage stability of these droplets will be 
investigated. The stability will be determined by how well these droplets maintain their 
sizes over time in a specified temperature environment. These experiments involve four 
different perfluorocarbons (Table 1.2), which have different structures and boiling points 
(Table 1.3) that may affect their stability. 
a) 
Droplets 
O<j& \ 
Endothelial Cells 
c) 
• • 
• • 
Tumor Cells 
b) 
-~~~ 
• • 
. : .. 
d) 
Ultrasound Transducer [ J 
c==:::, 
~ 
Microbubb/es 
Figure 1.3. Schematic of in vivo application of probubble precursor design. (a) Droplets traveling 
intravenously. (b) Droplets passively diffusing to extravascular space and binding to tumor cell 
receptors. (c) Droplets are internalized into tumor cells. (d) After 1-2 days to allow time for 
circulation, EPR effect, and physiological washout, ultrasonic force is applied to provide thermal and 
mechanical energy for droplets to undergo non-inertial cavitation into microbubbles. 
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Table 1.2. Chemical structures of erfluorocarbons used in this stud . 
Perfluorocarbon Chemical Structure 
F 
Perfluorohexane 
F 
F 
Perfluoro(2-methyl-3-pentanone) 
F F 
F F 
F 0 F 
F F F F 
F F 
Perfluoropentane 
F F 
F F 
F 
F 
Perfluorobutane F 
F 
F 
F 
5 6 Table 1.3. Physical properties of pertluorocarbons (' Lide 2010, Chemical Book 2008b). 
Popular name CAS Molecular Boiling Liquid Molecular Density weight (acronym) number formula point (°C) (g/mL) (g/mol) 
Perfluorohexane5 355-42-0 C6F14 56.6 1.71 338 (PFH) 
Perfluoro(2-
methyl-3- 756-13-8 CsF120 49.2 1.6 316 pentanone)6 
(PFMP) 
Perfluoropentane5 678-262 CsF12 29 1.63 288 (PFP) 
Perfluorobutane5 355-25-9 C4F10 -1.7 1.594 238 (PFB) 
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1. 7. Theory 
1. 7.1. Ideal Gas Law and Non-inertial Cavitation 
It is assumed that perfluorocarbon gases obey the ideal gas law (Equation 3). 
Therefore, the volume expansion of a PFC droplet can be determined. 
PV = nRT Equation 3 
P is the pressure in atmospheres, V is the volume in liters, n is the number of moles of 
perfluorocarbon, R is the gas constant, and T is the temperature in Kelvin. The following 
is an example forming a large bubble starting from a droplet that is 200 nm in diameter: 
Starting with a 200 nm diameter droplet and neglecting the thickness of the 
membrane, the spherical volume is 4.2 x 10- 15 mL. 
If the perfluorocarbon is a liquid, the number of moles of perfluorocarbon could 
be calculated based on the liquid density and molecular weight of perfluorocarbon 
(properties listed in Table 1.3). Average normal body pressure is roughly 90 mm Hg 
(0.12 atm) and will be deemed negligible for these calculations. 
4 2 10_15 L 1.63g PFP mol PFP 2 4 10-11 l PFP n= . x m x---"--x----= . x mo 
mL 288g PFP 
Assume P = 1 atm and T = 310.13 K (37°C) 
Use R = 0.0821 L•atm/mol•K and use Equation 3 to solve for V: 
V = nRT = 2.4 x 10-17mol PFP x 0.0821L · atm/mol · K x 310.13 K 
P 1 atm 
V = 6.0 x 10-16L = 6.0 x 10-13 mL = 6.0 x 108 nm3 
Solve for final diameter (cir) using final volume 
V = 6.0xl08 nm3 = 4 m-3 
3 
r = .,W = 3x6.0x10s nm3 = 524.3 nm 
I v~ 4~ 
dr = 2r1 = 2 x 524.3 nm = 1048.6 nm 
Compare the initial and final diameters to determine the expansion factor: 
dr = 1048.6 nm= 5 _243 
d; 200 nm 
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Therefore, the increase in bubble size from droplet diameter should be around a factor of 
5.2. When considering all of the perfluorocarbons, the range of increases is around 5-5.5 
(Appendix A) times the original droplet diameter depending on initial droplet size or, 
more directly, the initial amount of perfluorocarbon. Thus, a 1 µm diameter bubble 
should derive from approximately a 200 nm diameter droplet. 
I. 7.2. Per.fluorocarbon Droplet Diameter Based on Vapor Pressure 
The vapor temperature of perfluorocarbons can be estimated as a result of 
encapsulation within a membrane (Rapoport, et al., 2009). This relationship is a 
modified version of the Antoine equation (Equation 4) where Laplace pressure is taken 
into consideration. 
B log P=A---
10 T+C 
where P : vapor pressure 
T : absolute temperature (K) 
Equation 4 
A,B,C: Antoine equation constants particular for a substance 
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It is assumed that the membrane is a solid structure to approximately account for 
Laplace pressure. Therefore, the vapor pressure can include Laplace pressure, which is a 
difference in pressure (Equation 5). 
2a 
AP = pinside - poutside = -
r 
Equation 5 
where Pinside: pressure inside the droplet 
poutside : pressure outside of the droplet 
a: surf ace tension 
r : droplet radius 
Incorporating in Equation 5 into Equation 4, where AP will be included in P (now the 
absolute pressure, which is the sum of atmospheric, body, and droplet pressures) provides 
a relationship of vapor temperature as a function of droplet radius (Equation 6). 
B T=--~------C 
A - loglO( palm + P body+ 2;) 
Equation 6 
So, the vaporization temperature (T) of a droplet can be estimated from the droplet's size. 
The surface tension for the lipids used in this study is typically 51 mN/m, and the 
component constants were taken from NIST Chemistry Webbook (Linstrom and Mallard 
2010). Figure 1.4 shows the relationship between the vaporization temperature and the 
droplet diameter based on the Antoine equation relationship (Equation 6) for various 
perfluorocarbons. Theoretically, perfluoropropane has the potential to become 
encapsulated within a droplet that is 100 nm in diameter, which is estimated to have a 
vapor temperature of 35°C. Thus, the other PFC droplets could potentially be 
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encapsulated at room temperature while their vapor temperatures are much higher than 
perfluoropropane for 100 nm droplets. 
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Figure 1.4. Estimated vapor temperature ofperfluorocarbon within a droplet. The corresponding 
Excel setup can be found in Appendix B. 
1. 8. Prior Works 
There have been several studies of droplets and their conversions to microbubbles 
performed in the past decade. For example, some studies have involved the targeting of 
drugs directly to the tumor site via nanoparticle precursors (Nam, et al., 2009). The main 
differences between their design and the one proposed here are the membrane structures 
and how the droplets are prepared. Other studies use biodegradable block copolymers 
that resemble lipid structures (Gao, et al., 2008, Nam, et al., 2009), and they rely on the 
self-assembly of droplets due to the natural interactions between the perfluorocarbons, 
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block copolymers, and aqueous solution without a controlled homogenization technique, 
such as the use of a membrane for predetermined sizes. Thus far, the studies have found 
that their droplets can convert to nano/microbubbles upon heating, and the nanobubbles 
do coalesce to form larger, visible bubbles (Gao, et al., 2008). They were even able to 
design a tumor-selective droplet (Gao, et al., 2008). Sonication was the most efficient for 
non-inertial cavitation of a droplet to a microbubble (Rapoport, et al., 2009), which 
supports the reasoning for our device design. 
Kripfgans and coworkers have studied larger droplet sizes(> 4 µm) that would be 
limited to the vascular space design especially for occlusion therapy in capillary beds 
(Kripfgans, et al., 2000, Kripfgans, et al., 2002). Their droplets were developed with 
perfluoropentane and a shell of denatured albumin. These researchers found that an 
increase in acoustic intensity was required for expanding smaller droplets (Kripfgans, et 
al., 2004), which supports our design rationale. 
I. 9. Specffic Aims and Hypotheses 
Specific Aim 1: To determine the stability of droplets with similar lipid 
composition but different perfluorocarbon core content, and to determine the stabilities of 
perfluorocarbon droplets under different temperatures over a period of 16 weeks. A 
similar study was done where the stability of 1,2-trans(bisperfluorobutyl)ethylene 
droplets was monitored (Burgess and Yoon 1995). Our studies expand their report by 
using various perfluorocarbons and methods to obtain more uniform samples. 
Hypothesis: We hypothesize that the perfluorohexane droplet will show the 
greatest stability relative to the other perfluorocarbon droplets due to its higher boiling 
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point. The other perfluorocarbon droplets will expand due to being more volatile (lower 
boiling points) compared to perfluorohexane. 
The stability of the droplets will be monitored via the Malvern Zetasizer Nano ZS 
particle size machine. It provides an inherent standard error of ±10 percent from the 
standards of 100 nm, 200 nm, and 400 nm reference beads (NanosphereTM Size Standards 
- 3000 Series, Thermo Scientific, Fremont, CA). A sample of droplets will be 
determined to be stable if the droplets maintain the same z-average size ( average 
diameter based on dynamic light scattering intensity) or size profile (size distribution of 
sample based on intensity) over time compared to its z-average baseline value within a 10 
percent standard error. 
Specific Aim 2: To determine the vaporization threshold of droplets as a function 
of diameter, boiling point, and partial pressure. 
Hypothesis: The vaporization threshold of droplets with perfluorocarbons of 
higher boiling points will be much higher than those droplets with perfluorocarbons of 
lower boiling points as predicted by the Antoine equation. Ultrasound energy induces 
mechanical and thermal effects that can cause liquid perfluorocarbons to vaporize. 
Perfluorohexane has the highest boiling point of the group of perfluorocarbons to be 
tested and, thus, should be more difficult to vaporize than a perfluorocarbon having a 
lesser boiling point. Droplets that require mechanical indices less than 1. 9 will be 
considered for eventual in vivo studies. 
Specific Aim 3: To encapsulate liquid perfluorobutane within lipid shells in order 
to form metastable droplets. 
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Hypothesis: We hypothesize that we can make metastable droplets that match our 
criteria of stability and vaporization. A perfluorocarbon with a boiling point less than 
room temperature may be stabilized in lipid shells or emulsions as a metastable droplet 
for use at body temperature (37°C). Such a droplet would be potentially beneficial by 
allowing use of less ultrasonic output energy in order to limit or eliminate bioeffects. 
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2. MATERIALS AND METHODS 
2.1. Preparation of Per.fluorocarbon Droplets 
Initially, lipid thin films were prepared with a composition containing 85 mole 
percent dipalmitoylphosphatidylcholine (DPPC), 10 mole percent 1-palmitoyl-2-
hydroxy-sn-glycero-3-phosphocholine (LPC), and 5 mole percent 1,2-dipalmitoyl-sn-
glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000] (DPPE-PEG 
2000) (Avanti Polar Lipids). The lipids were dissolved in less than 1 mL of chloroform 
(EMD Chemicals) and gently evaporated with nitrogen gas. The lipids were lyophilized 
(VirTis Freezemobile 25EL Sentry 2.0 Lyophilizer) overnight to remove residual solvent 
and create lipid films. 
The lipid films were rehydrated with approximately I mL of HEPES ( 4-(2-
hydroxyethyl)piperazine-1-ethanesulfonic acid) buffer (pH = 7.4) and sonicated for 10 
minutes in a water bath sonicator (Branson 1510, Danbury, CT) at 50-60°C. The 
rehydrated films were subjected to 10 freeze-thaw cycles, first freezing with an 
isopropanol bath with dry ice followed by thawing with a 50-60°C water bath. This 
created a homogeneous lipid suspension, which was also stirred for 10 minutes at 50-
600C immediately afterwards. The resulting concentration of the lipid solution was about 
20 mg/mL. 
The perfluorocarbons used were perfluorohexane (PFH), perfluoro(2-methyl-3-
pentanone) (PFMP), and perfluoropentane (PFP). PFH and PFP were purchased from 
FluoroMed (Round Rock, TX). PFMP was purchased from SynQuest (Alachua, FL). 
Their physical properties are listed in Table 1.3. Each perfluorocarbon was added to the 
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lipid solution (20% v/v), and multiple extrusions were performed using an Avanti Mini-
Extruder (Avanti Polar Lipids, Alabaster, AL) with polycarbonate membrane filters 
(Whatman Nuclepore Polycarbonate Track-Etch Membrane) at room temperature (23°C). 
Membrane filters with 200 nm pores were used for stability tests, and filters with 1 µm 
pores were used for acoustic droplet vaporization (ADV). Normally, extrusions would 
occur at temperatures above the phase transition temperature of the lipids, but we 
performed the extrusions at room temperature due to the boiling point of PFP. Extrusions 
were completed after 20 passes through the membrane. The resulting solutions 
underwent centrifugation (Beckman Model TJ-6 Centrifuge) for 15 minutes and between 
800 and 1000 rpm. For stability tests, the samples were stored immediately in a 
refrigerator at 4°C, in a styrofoam container at 23°C, or in an oven at 40°C. For ADV 
tests and further sizing, the samples were stored in a styrofoam container with a 
refrigerated ice pack and sent to Dr. Paul Dayton's laboratory located at the University of 
North Carolina (UNC). 
2.2. Preparation of Perjluorobutane (PFB) Droplets 
For the PFB droplets, the same lipid solutions were used, but the procedures 
differed when introducing the PFB. First, the PFB gas (FluoroMed, Round Rock, TX) 
was condensed in an Exacta-Mix™ EVA Container over dry ice. The condensed PFB 
was poured into a 2 mL glass vial and crimped. It was impossible to perform an 
extrusion after adding the PFB to the lipid solution. Instead, the lipid solution was added 
to condensed PFB in the glass vial and shaken on a modified "dental shaker" (VialmixTM, 
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120V/60Hz, Bristol-Myers Squibb Medical Imaging, Inc., North Billerica, MA) for 45 
seconds. 
As a modification to the above methodology, glycerol (Sigma) was added to the 
lipid solution (20% by volume) prior to performing the extrusion. Glycerol is commonly 
used as a cryoprotectant for blastocysts (Cohen, et al., 1985 and Fehilly, et al., 1985). 
Thus, it should most likely provide a protective shell around the lipid membrane in 
addition to the liquid PFB. Similarly, methods presented by Pan and Wang (Wang and 
Pan 1994 and Pan, et al., 1999) introduced their use of glycerol to make superheated-
liquid droplets of Freon-12, which has a boiling point of -29.8°C (Lide 2010). 
Upon entering a -20°C walk-in freezer, 200 µl of PFB was extracted and added to 
the lipid solution. A 13 mm diameter syringe holder (KS13, Advantec MFS, Dublin, CA) 
was used instead of the Avanti Mini-Extruder where an additional female luer-lok was 
attached to the outlet with the appropriate male luer slip. Here, a 1 µm porous membrane 
filter was also used, ancj. extrusions were completed after 20 passes through the 
membrane. The emulsion was placed in a 2 mL vial, crimped, and stored at 4 °C. Storing 
the resulting emulsion at -20°C would cause the lipids to potentially fall out of position as 
they thaw. 
2. 3. Identification of Droplet Storage Stability 
The Malvern Nano ZS particle size analyzer (Malvern Instruments Ltd., Malvern, 
Worcestershire, UK) has an inherent standard error of 10 percent with standards of 100 
. nm, 200 nm, and 400 nm reference beads (Nanosphere TM Size Standards - 3000 Series, 
Thermo Scientific, Fremont, CA). The stabilities of the perfluorocarbon droplets were 
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determined based on how long the droplets maintained their z-average sizes over time 
within 10 percent from their baseline z-average sizes. Z-average size is a mean diameter 
based on the intensity of the dynamic light scattering result from a given sample. 
Perfluorocarbon emulsions were prepared specifically for sizing via dynamic light 
scattering on the particle size analyzer. Briefly, 150 micro liters of sample was introduced 
into a 12 mm disposable square polystyrene cuvette, 1 mL of HEPES buffer was added, 
and the cuvette was capped. The z-average sizes were monitored immediately after 
preparation (week 0), week 2, week 4, week 8, week 12, and week 16. Sixteen weeks 
would represent a short-term storage stability study following FDA guidelines for drug 
stability (Bensley 2008). Raw data and data analysis for the stability study can be found 
in Appendix C. 
2. 4. Scanning Electron Microscopy (SEM) 
SEM was performed at the University Spectroscopy and Imaging Facilities 
(USIF) at the University of Arizona. A drop of each sample (PFP or PFB droplets) was 
spread over a 1 cm2 piece of silicon on top of an aluminum stub. The samples were then 
left to dry under a fume hood where the PFP sample remained as a thin layer of liquid 
solution whereas the PFB sample became foamy in appearance as a result of the drying 
process. The samples were coated with platinum under a plasma chamber for about 10 
minutes. Samples were examined under SEM (Hitachi S-4800 Type II) simultaneously 
along with the energy dispersive x-ray (EDS) analyzer (ThermoNORAN NSS EDS), 
which was used to further confirm SEM results. Primarily, detection of fluorine was used 
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as a key indicator for the presence of any perfluorocarbon. All samples were viewed with 
back-scattering electrons. 
2. 5. Transmission Electron Microscopy (TEM) 
Oftentimes, it is necessary to perform freeze-fracture transmission electron 
microscopy (TEM) in order to maintain the inherent integrity of cellular structures or, in 
this case, emulsions. However, Chetanachan et al. (2008) suggested a potential negative 
staining technique to visualize liposomes via TEM at room temperature. Even though 
droplets are essentially emulsions and are not bilayer structures like liposomes, both 
contain lipid membranes that can be stained for TEM. Therefore, a similar method was 
used with a few slight modifications to the procedure. 
TEM was performed at USIF at the University of Arizona. Briefly, PFP and PFB 
droplets were prepared by inserting a drop of perfluorocarbon droplet solution between a 
0.5 cm2 carbon and mica layer (the sample diffused through the spacing between the 
substances). The carbon-sample-mica segment was inserted at a 45° angle into a small 
well of 2% phosphotungstic acid (pH = 7.4) for staining of the phospholipids. This also 
allowed for the carbon layer to float across the top of the well containing the sample. The 
carbon layer was scooped up with a 400 mesh copper grid and wicked onto filter paper. 
The sample was ready for TEM analysis using a JEOL 1 00CX II TEM. 
2. 6. Freeze-Fracture TEM 
Dr. Brigitte Papahadjopoulos-Sternberg did the freeze-fracture TEM. PFB 
droplets were prepared for freeze-fracture TEM using a quenched sandwich technique 
employing liquid nitrogen-cooled propane at a cooling rate that avoids ice crystal 
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formation and artifacts secondary to the cryofixing process. Samples were processed 
within two hours after liquid nitrogen storage. Fracturing was conducted using a JEOL 
JED-9000 with freeze etching and fracture planes shadowed with platinum for 30 seconds 
at an angle of 25° to 35° followed by treatment with carbon for 35 seconds. Replicas 
were cleaned with fuming nitric acid and chloroform/methanol. Images were examined 
on a JEOL 1 00CX TEM. 
2. 7. Experimental Apparatus 
Perfluorocarbon droplet samples were shipped to Paul Sheeran at the University 
of North Carolina (UNC) in a styrofoam container along with a refrigerated gel pack. All 
apparati for acoustic droplet vaporization (ADV) tests were designed and constructed by 
Paul Sheeran in the laboratory of Professor Paul A. Dayton at UNC. According to 
Sheeran and colleagues, "a water bath constructed of acrylic was mounted on top of an 
inverted microscope (Olympus IX71) and interfaced with a high-speed camera (FastCam 
SA 1.1, Photron USA, Inc.) to capture monochrome videos and still images of particles 
and microbubbles. A IO0X NA=l.0 water immersion objective was used to provide 
image magnification. The optical resolution of the system was measured to be 0.5 µm, as 
determined by a calibrated line pair test slide (Max Levy Autograph, Inc.). Baseline 
water oxygen saturation was measured to be 5 PPM at 3 7°C, as measured by a chemical 
test kit (Oxygen CHEMets, CHEMetrics, Inc). In the case of degassed experiments, an 
in-line degasser was allowed to operate until the water oxygenation in the water tank 
measured less than or equal to 1.5 PPM. The water bath was passively heated to a 
consistent 37°C by heating water in an auxiliary tank and continuously pumping it 
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through copper coils lining the main tank such that vibration in the water bath was 
minimiz.ed (Figure 2.1). The temperature of the auxiliary tank was adjusted until the 
desired temperature of the water in the experiment region of the main tank along with any 
additional light heating was reached. The droplet solution was pumped through a nearly 
optically and acoustically transparent cellulose tube with a 200 µm inner diameter 
(Spectrum Labs, Inc.) using a custom-built manual injector allowing for precise 
administration of the droplets into the field of view. A 3-axis micropositioner (MMO-
203, Narishige Group) was used to manipulate the sample holder and, therefore, the 
droplets/bubbles in the field of view. By this means, we were able to locate and 
manipulate droplets to stay on-screen throughout the test and track the resulting bubbles'' 
(Sheeran, et al., 2011). 
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Figure 2.1. Experimental setup (unpublished figure courtesy of Sheeran, et al, 2011). High-speed 
camera captured two-dimensional images of droplets and bubbles. 
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2.8. Acoustics 
According to Sheeran and colleagues, "a spherically focused 5 MHz transducer 
with a focal length of 3.8 cm (IL0506HP, Valpey Fisher Corp., Hopkinton, MA, USA) 
was used to insonify droplet samples. The transducer had a -6 dB beam widths of 0.7 
mm laterally and 13.2 mm axially for peak positive pressure, while widths were 1.3 mm 
laterally and 22.8 mm axially for peak negative pressure. Waveforms were constructed 
using an arbitrary waveform generator (AWG 2021, Tektronix, Inc., Beaverton, OR, 
USA), which allowed for adjustment of the transmission waveform pulse length and 
amplitude. Two manually-triggered signals of adjustable amplitude were used for these 
experiments: 1) a 10-cycle sinusoid at 5 MHz resulting in a total insonification time of 2 
ms, and 2) a 10,000 cycle sinusoid at 5 MHz resulting in a total insonification time of 2 
ms, following the results of Lo et al. (2007). A synchronization pulse from the waveform 
generator was relayed to the high-speed camera in order to trigger a marker with the 
acoustic pulse on the digital video. The waveform from the function generator was 
amplified approximately 60 dB using an RF amplifier (A500, ENI) in order to excite the 
transducer. For optical-acoustic alignment, the transducer focus was matched with the 
optical focus by positioning the tip of a needle hydrophone (HNA-0400, Onda Corp.) in 
center of the microscope field of view. The transducer was then calibrated at focus over 
the range of amplitudes used so that the pressure exerted on the droplets in the field of 
view was known" (Sheeran, et al., 2011). 
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3. RESULTS 
3.1. Storage Stability 
The z-averages of each sample are plotted in Figures 3 .1, 3 .2, and 3 .3 for storage 
temperatures of 4 °C, 23 °C, and 40°C, respectively. The samples stored at 4 °C remained 
stable for the entire 16 weeks and did not deviate too far from their baseline z-average 
values. Not all of the samples had the same initial diameter (Figures 3.2 and 3.3) even 
though all homogenizations were performed with a 200 nm membrane filter. 
Perfluorocarbon droplets exhibited large deviations from baseline z-average values at 
23°C and 40°C. Also, some samples evaporated at 23°C and 40°C where some data 
could not have been obtained. The corresponding raw data can be found in Appendix C. 
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Figure 3.1. Z-averages for nine samples that were stored at 4°C and monitored for 16 weeks. 
Samples 1-3 are PFH droplets, samples 4-6 are PFMP droplets, and samples 7-9 are PFP droplets. 
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Figure 3.2. Z-average!! for nine samples that were stored at 23°C and monitored for 16 weeks. 
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Samples 1-3 are PFH droplets, samples 4-6 are PFMP droplets, and samples 7-9 are PFP droplets. 
Missing data points are due to errors with data acquisition and/or evaporation ofsample. 
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Figure 3.3. Z-averages for nine samples that were stored at 400C and monitored for 12 weeks. 
Samples 1-3 are PFH droplets, samples 4-6 are PFMP droplets, and samples 7-9 are PFP droplets. 
Not enough sample was left for data acquisition at 16 weeks. 
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If the droplets maintained their z-average values within ten percent compared to 
the corresponding baseline z-average values, then the droplets were determined to be 
stable. Appendix C describes the method for how stability was determined. Figures 3.4, 
3.5, and 3.6 show the deviation from baseline droplet sizes over a 16 week period at 4°C, 
25°C, and 40°C, respectively. The error bars are large because they represent the 
standard deviation of three individual samples that may vary in z-average size. The 
average deviation of the droplets was less than ten percent from the baseline values at 
4 °C and throughout most of the test period for 23 °C. PFH droplets were the least stable 
compared to the other droplets at 4 °C. At 23 °C, PFMP droplets deviated a little over ten 
percent after the first two weeks but later stabilized closer to baseline values and 
evaporated after 12 weeks. PFP droplets had deviated 31 % and 4 7% away from baseline 
z-average values at weeks 4 and 12, respectively, but they were near baseline values at 
week 8 when stored at 23°C. 
Moreover, most of the droplets were far from their baseline values after the first 
two weeks at 40°C. Specifically, the z-average values were smaller compared to baseline 
values. This suggests that evaporation of the perfluorocarbons occurred after the first two 
weeks, and there was potential self-assembly of liposomes of smaller sizes. Thus, the 
data suggests greater stability at cooler temperatures. 
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Figure 3.4. Average percent deviations of each group of perfluorocarbon droplets compared to week 
0 at 4°C. Average percent deviations were no greater than 10% from original sizes over 16-week 
period. Error bars are large because they represent the standard deviation of 3 samples that vary in 
z-average size (p = 0.01). 
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Figure 3.S. Average percent deviations of each group of perfluorocarbon droplets compared to week 
0 at 23°C. Droplets were monitored over 16-week period. Missing data points due to evaporation of 
samples. Error bars are large because they represent the standard deviation of 3 samples that vary 
in z-average size (p = 0.14). 
-10.00 
-30.00 
--40.00 
= -5 .00 
.: 
~ 
·s: 
" Q 
-6 .00 
E 
" ... .,
0.00 0. 
-
-
0.00 
-9 .00 
-1 .00 
2 -I 
Week 
PFP 
PFMP 
45 
PFH 
I_ 
Figure 3.6. Average percent deviations of each group of perfluorocarbons compared to week O at 
400C. Droplets were monitored over 12-week period. Missing data points due to evaporation of 
samples. Error bars are large because they represent the standard deviation of 3 samples that vary 
in z-average size (p = 0.26). 
Figures 3.7, 3.8, and 3.9 show the size distributions by intensity obtained from the 
particle size analyzer of perfluorohexane droplets. Figures 3.7 and 3.9 show that the 
baseline size distributions were bimodal. This suggests that not all of the samples can be 
reproduced with uniform distributions with the methods performed. In general, the size 
distribution for the PFH droplet sample at 4°C (Figure 3.7) remained the same although 
PFH droplets were the least stable compared to the other droplets at that temperature. 
However, Figures 3.8 and 3.9 show that the samples did consequently become unimodal 
after 16 weeks. The size distributions shown in Figures 3.8 and 3.9 also exhibit the 
average sizes of the droplets becoming smaller. 
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Figure 3.7. Size distributions by intensity ofperfluorohexane sample stored in 4°C for 16 weeks. 
Size distribution was bimodal for week O and week 16 suggesting a nonuniform sample but still 
maintained relatively the same size distribution. 4°C is ideal for storage of droplets. 
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Figure 3.8. Size distributions by intensity of perfluorohexane sample stored in 23°C for 16 weeks. 
Size distributions shifted slightly to the left over time suggesting that majority of the droplets became 
smaller. The size distribution was more steep at week 16 suggesting a more uniform distribution. 
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Figure 3.9. Size distributions by intensity of perfluorohexane sample stored in 40°C for 12 weeks. 
No data was obtained for week 16 due to evaporation of samples. Size distributions shifted to left 
suggesting droplets became smaller over time. 
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3.2. Acoustic Droplet Vaporization (ADV) 
PFC droplets were sent to UNC for ADV tests, which is also where data was 
collected and analyzed by Sheeran and colleagues. PFH droplets were observed to not be 
able to vaporize at all test parameters of ultrasound output energy. This inherent stability 
of PFH is attributed to its high boiling point and the stability of the outer shell of the PFH 
droplets. On the other hand, the other perfluorocarbons were able to vaporize. Figure 
3.10 shows vaporization thresholds (Mls) as a function of diameter. PFB droplets 
required less MI, which translates to requiring less ultrasound output energy, than PFP 
and PFMP droplets in order to vaporize. The larger droplets required less MI than 
smaller droplets, which was similar to other reported results (Kripfgans, et al., 2004). 
The raw data was extrapolated beyond the range of the collected data, especially for PFP 
and PFB droplets, which should not have happened. Also, for the fit for PFMP, there 
appears to be a significant drop-off beyond 21 µm. 
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Figure 3.10. Mechanical Index versus initial droplet diameter. Each droplet diameter required a 
specific MI in order to become vaporized (vaporization thresholds). PFB required less ultrasound 
output energy than PFMP and PFP. Each tick mark on mechanical index scale represent five 
hundredths. 
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Stable droplets were isolated and recorded for set pulse lengths of 2 µs or 2 ms. 
Figure 3 .11 a shows still images of an isolated stable droplet that laterbecame a bubble 
after ADV. Immediately after application of ultrasound output, PFP and PFB droplets 
showed an increase in diameter by an average factor of 10.39 ± 2.27 in solution that had 
not been degassed within the allotted pulse length times (Figure 3.12). The bubbles in 
solution that had not been degassed continued to grow an average of 21.9% of their 
original bubble diameter (taken at final pulse length). When the solution was degassed, 
droplet diameters increased by an average factor of 6.24 ± 0.58, and those bubbles 
continued to grow an average of 3 .6% of their original observed diameters ( also taken at 
final pulse length). This is closer to the estimated calculated value from the ideal gas 
law, which suggests that the droplets should increase between 5 and 5.5 times their 
original diameters. Volume was not monitored nor recorded directly due to the 
limitations of the experimental setup; therefore, it was easier to identify a diameter with 
the two-dimensional images that were acquired. Moreover, the greater increase in size in 
solution that had not been degassed suggests that perfluorocarbons have the innate ability 
to absorb excess gas in its environment (see Section 4.2), which is also dependent on the 
concentration of the excess gases in the environment. 
Figure 3.11. Before and after pictures ofan isolated and stable PFB droplet. a) PFB droplet is 
roughly S p.m in diameter. b) PFB droplet becomes a 20 p.m in diameter bubble after acoustic 
droplet vaporization (ADV). 
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Figure 3.12. Relationship between initial and final diameters in solution for PFCs with boiling points 
less than 37°C. The trends are consistent and not dependent on PFC type. Degassed solution 
exhibited an increase by a factor of 6.24 :i: 0.58 while solution that bad not been degassed exhibited 
increases by a factor of 10.39 :i: 2.27 from the original diameter. 
For PFC droplets with boiling points greater than normal body temperature (3 7°C), 
PFH did not vaporize under the experimental conditions. On the other hand, PFMP did 
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vaporize but did not show any differences when vaporized in degassed and undegassed 
solutions (Figure 3.13). While the experimental conditions and data acquisitions were 
similar as those done for PFP and PFB, there was a spot in the nuclei of the droplets. 
This suggests that the nuclei were just entering the gaseous phase, and full expansion of 
droplets did not occur until much later after ultrasonic power was applied. 
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Figure 3.13. Relationship between initial and final diameters in solution for PFMP droplets. PFMP 
droplets did not fully vaporize at final pulse length measurement. 
3. 3. Encapsulation of Perjluorobutane 
Initial attempts were made to encapsulate liquid PFB inside a lipid membrane. The 
first attempt involved the use of the Avanti Mini-Extruder after adding PFB to the lipid 
solution at room temperature (23°C). Extrusion was deemed impossible because most of 
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the PFB had vaporized upon addition to the lipid solution. Therefore, the next attempt 
involved insertion of the lipid solution into the PFB glass vial followed by shaking on the 
"dental shaker". There were two liquid layers because a pressure head containing 
"excess" PFB gas may have formed. Therefore, efforts were made to capture the size of 
PFP (Appendix D) and PFB droplets via SEM, TEM, and dynamic light scattering. It 
was expected to see the nanodroplets as spherical structures; however, the structures of 
the perfluorobutane sample appeared as holes in SEM images (Figure 3.14a), which were 
verified by the EDS in addition to tilting the sample (Figure 3 .l 5a). The fluorine 
detection from the EDS for the PFB sample showed that the fluorine had dispersed into 
the web-like structure that had formed as a result of the air-drying process for SEM 
sample preparation in addition to the nature of the perfluorocarbon (Figure 3 .15b ). 
However, the results appear equivocal considering the boiling point of the PFB and the 
isolation process of the droplets. 
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Figure 3.14. Screenshot of computer software interface containing a) SEM image and b) EDS result 
obtained for PFB droplet sample. c) Periodic table of elements showing which have been identified. 
d) EDS spectra. Fluorine peak is indicative of presence of PFB. 
Figure 3.15. SEM and EDS results of PFB sample. a) PFB sample tilted highlighting 
perimeters of holes. b) EDS of perfluorobutane sample showing dispersion of fluorine (blue 
content) in web-like structure. 
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As demonstrated by a TEM image of PFB droplets (~100 run) prepared at room 
temperature (25°C), the membrane structures of the PFB sample appear to be thick and 
most likely have more than one layer (Figure 3.16). It is unclear as to whether or not this 
is representative of the actual PFB droplets or if they are bubbles as a result of their 
natural tendency to vaporize. 
Figure 3.16. TEM image of PFB droplet sample prepared at room temperature. Membranes appear 
to have more than one layer. 
The population of PFB droplets (Figure 3.16) was not distributed throughout the 
entire TEM grid and was recognized as not being a uniform sample. Also, PFB droplets 
vaporized immediately at room temperature; therefore, PFB droplets were prepared for 
analysis via freeze-fracture TEM (Figure 3.17). The droplets are between 20 and 40 run 
in diameter. However, such droplets would not work for ultrasound imaging because the 
droplets would then result in approximately 200 run diameter bubbles that are too 
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difficult to visualize with ultrasound imaging because of their size and their likelihood to 
rapidly collapse due to Laplace pressure. These particles are more likely to be lipid 
particulates remaining after extrusion. 
100nm 
Figure 3.17. Freeze-fracture TEM image of putative PFB droplets. They are 20-40 nm in the 
background. 
It was impossible to obtain a precise measurement reading from the dynamic light 
scattering for PFB droplets because the sample was too polydisperse suggesting that the 
PFB droplets were not uniform in size after preparation for the particle size analyzer. 
Therefore, the PFB droplets were then further stabilized with lipids and glycerol for ADV 
experiments. Fluorine content could not be detected after SEM preparation of these new 
droplets, and no clear or defined structures of droplets were found with TEM. 
55 
4. DISCUSSION 
Perfluorocarbon droplets were investigated m terms of storage stability, 
formulations, and vaporization. 
4. I. Storage Stability of Perfluorocarbon Droplets 
The shelf-life stability of perfluorocarbon droplets is important because it is 
necessary to identify how long this formulation could potentially be stored after 
preparation should this type of formulation become a diagnostic or pharmaceutical tool. 
The droplets were more stable in a 4 °C environment with an average deviation of less 
than 10 percent from the baseline values. Therefore, the droplets should be stored at 4 °C 
prior to testing. Temperatures above 4°C increase risks for droplet degradation, 
aggregation, or coalescence. There appeared to be no relationship between boiling point 
and stability, although PFH droplets were the least stable at 4 °C and 40°C while PFMP 
droplets were the least stable at room temperature (23°C). 
The size distributions based on the light scattering intensity of the 
perfluorocarbon droplets varied over time at the three temperature settings. This 
variation in distribution may be a result of aggregation and coalescence of the droplets 
(Ostwald ripening) (Basude, et al., 2000). In addition, the distributions were based on 
intensity, and the intensity-weighted scattering of the particle sizer is proportional to the 
diameter of the droplet raised to the sixth power. Therefore, one large particle/droplet 
can skew the size profiles. Nonetheless, the distribution of droplets remained roughly the 
same at 4 °C suggesting that such an environment provides more stability. The 
distribution of droplets became more uniform over time at 23°C and 40°C. Also, the 
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interactions between the lipids, perfluorocarbons, and HEPES buffer may stabilize to a 
favorable state of uniformity on their own. Although the samples were capped, this still 
may be the result of evaporation of the samples, as they lost volume over time. The 
perfluorocarbons may have evaporated before water because of their lower boiling points. 
The evaporation of perfluorocarbon may have left the lipids to spontaneously form 
liposomes of uniform size. It is also possible that the particle size detector may have 
detected smaller droplets more frequently than larger sized droplets. 
4. 2. Vaporization Thresholds of Perjluorocarbon Droplets 
Perfluorocarbon droplet samples were subjected to vaporization testing. PFMP, 
PFP, and PFB droplets vaporized with the set experimental parameters while PFH 
droplets did not vaporize due to having higher vaporization thresholds. PFP and PFB 
droplets were able to vaporize with mechanical indices less than the FDA accepted 
maximum clinical setting (Ml = 1. 9) (Figure 3 .10). However, the visualized droplets 
were greater than 1 µm in diameter, and the desired 200 nm droplets were not easily 
visible. The ultrasonic energy might not only provide thermal energy, but it might also 
provide mechanical energy such that the droplets and/or bubbles might aggregate and 
coalesce to form larger droplets/bubbles, also known as Ostwald ripening (Rapoport, et 
al., 2007). This may result in further stabilization of some of the droplets/bubbles. In 
addition, the mechanical energy might cause the membranes to oscillate and eventually 
undergo inertial cavitation where the bubbles would collapse, especially affecting smaller 
bubbles. 
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From the ADV experiments, it appears that vaporization factors include the 
surrounding environment (gases in solution), the droplet sizes, and acoustic output. If 
there is gas present in the surrounding environment, the perfluorocarbons may have a 
tendency to absorb the gas, which would produce much larger bubbles than calculated 
from the ideal gas laws. The absorption of environmental gases is not surprising because 
perfluorocarbon liquids have been used as oxygen carriers for blood substitutes (Biro, et 
al., 1987 and Spahn, et al., 1994). For future in vivo experiments, the amount of excess 
gas would definitely be variable, and the perfluorocarbon droplets may expand similar to 
their expansion in solution that had not been degassed. Also, larger droplets had lower 
vaporization thresholds than smaller droplets because they may have had lower vapor 
temperatures as predicted. Therefore, the required thermal energy was greater for smaller 
droplets as they may have simultaneously coalesced to form larger droplets/bubbles upon 
heating (Gao, et al., 2008 and Rapoport, et al., 2007). While smaller bubbles (750 nm to 
1 µmin diameter) would derive from smaller droplets (150 nm to 200 nm in diameter), 
their higher vaporization thresholds might also derive from having less perfluorocarbon 
content, which would in tum result in absorption of less gas. The amount of 
perfluorocarbon contained in the droplet is relative to the droplet size, and heating of 
perfluorocarbon would produce bubbles of relative size that are about 5.5 times larger in 
diameter than the original droplet diameter as a result of non-inertial cavitation. 
The results from this work imply that it is possible to stabilize perfluorocarbon 
liquid within membrane shells. Although the perfluorobutane liquid required further 
stabilization with glycerol, the properties of the droplets were not impacted such that 
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lower Mis were required to vaporize the PFB droplets. Even though this may appear to 
be very promising in the design of a probubble that could eventually become an 
extravascular agent, the Mis used in the experiments especially for PFMP and PFP were 
near the upper range of Mis used in the clinical setting (Figure 3 .10). While the droplets 
tested were greater than 1 µm in diameter due to the optical limitations provided by the 
microscope, this also suggests that smaller droplets may require much higher Mis, which 
would most definitely be at risk for potential bioeffects in vivo. Therefore, encapsulation 
of lower boiling perfluorocarbons may need to be further explored. 
The increase in sizes was much greater for gassed solutions compared to degassed 
solutions (Figure 3.12). This difference is due to the nature of perfluorocarbons and their 
ability to absorb excess gases in their surrounding environments. For comparison, the 
average increase for the droplets in degassed solution was 6.24 ± 0.58 times the initial 
droplet size, which is very close to the calculated conversion of 5-5.5 times the droplet 
size according to ideal gas law calculations (Appendix A). Although the increase is still 
higher than the calculated factor, this may suggest that the solution was not entirely 
degassed and/or the smaller bubbles had aggregated and coalesced. A solution that is not 
degassed is representative of physiological conditions. Typically, it appears that the 
amount of oxygenation near a tumor site is dependent on the stage of the tumor where 
newer tumors tend to have more oxygenation due to neovascularization, and older 
malignant tumors are often hypoxic (Vaupal, et al., 1989). However, newer tumors 
might have hypoxic microenvironments, thus the surrounding environments near tumors 
remain unknown because of the constant changes that cancer can undergo. 
59 
Nevertheless, the increase in sizes from degassed solution can be used to estimate 
the initial droplet sizes. For example, a 30 µm diameter bubble would most likely have 
derived from a 5.5 µm droplet. The increase in size in degassed liquid suggests that the 
perfluorocarbons load excess gases spontaneously and rapidly. Perfluorocarbons do not 
necessarily react with the excess gases but rather only draw them into the 
droplets/bubbles, and thus, there exists a mixture of perfluorocarbons and other gases 
( oxygen, nitrogen, carbon dioxide). Hence, the average increase in bubble size is a little 
more than the theoretical value whereas the microbubble conversion in undegassed 
solution would be much greater due to absorption of more excess gas. Meanwhile, the 
perfluorocarbon content is probably maintaining the structural integrity of the bubbles 
because most air bubbles tend to collapse much more quickly than perfluorocarbon 
bubbles (Porter and Xie 1995). Other potential factors that may affect the expansion of 
the droplet to a bubble are the pressure and the surface tension. 
Furthermore, PFMP droplets converted to final bubble diameters tens of seconds 
later than PFP and PFB droplets. The nuclei of the droplets appeared to have had two 
phases (liquid and gas) suggesting the genesis of microbubbles. Hence, the state of the 
nuclei of the droplets/bubbles and the percentage of that state could determine how much 
excess gas the perfluorocarbon could absorb. In addition, this rate of conversion to gas 
could potentially lead to exploring higher boiling perfluorocarbons and determining the 
parameters to vaporize perfluorocarbons. A slower rate of data acquisition may be 
necessary for these studies than the acquisition rates that are currently available. 
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4. 3. Perjluorobutane Encapsulation 
Stable PFB droplets were formulated by usmg lipids, and they withstood 
temperatures up to 3 7°C. Encapsulation of PFB had to be conducted under pressure or at 
temperatures below the boiling point of PFB. However, the sizes of the PFB droplets 
were difficult to confirm via TEM or submicron particle sizing because the PFB droplets 
foamed upon insertion of a needle in order to extract some sample. TEM results (Figure 
3 .16) remain equivocal as to whether or not PFB droplets were capable of being imaged. 
Accurate particle sizing was impossible because particle size analysis suggested that the 
sample was too polydisperse. 
Consequently, glycerol was added to the PFB droplet formulation, which resulted 
in a more stable solution that did not foam upon insertion of a needle to obtain some 
sample. The glycerol prevented PFB droplets from instantaneously vaporizing when 
attempting to draw out the sample. Adding glycerol may have also increased the vapor 
temperature for PFB by providing a more solid membrane, which makes it more relevant 
to the Laplace pressure estimation. However, it remained difficult to assess PFB droplets 
with TEM. The particle size analysis provided the same polydisperse result. Further 
investigations of methods of identifying and visualizing these types of droplets may be 
necessary. 
61 
5. CONCLUSIONS 
5. 1. Conclusions on Storage Stability of Droplets 
The study demonstrated that the storage stability of perfluorocarbon droplets is 
not dependent on boiling point but is dependent on temperature storage conditions. It is 
important to keep the perfluorocarbon droplets refrigerated prior to use in ultrasound-
mediated applications. Droplets less than 1 µm in diameter can be made with the 
methods used in this study. Nonetheless, methods of developing a more uniform sample 
of perfluorocarbon-filled droplets need to be further investigated. Better containment of 
samples in future storage stability studies may be necessary to prevent evaporation of 
samples. 
5. 2. Conclusions on Vaporization Thresholds 
Four different types of perfluorocarbons were explored in order to investigate 
their vaporization thresholds as droplets. PFH droplets are not appropriate droplets for 
ultrasound-mediated applications because they require much greater energy for 
vaporization and will cause greater risk for potential bioeffects. PFB droplets may 
require ultrasound energy output within clinical ranges. Higher ultrasound energy output 
is required as droplet size decreases below 1 µm in diameter. Encapsulation of lower 
boiling perfluorocarbons may be necessary to use reasonable Mis for droplets 200 nm in 
diameter. Other methods for isolating and viewing smaller droplets need to be explored. 
5.3. Conclusions on Encapsulation of Perjluorobutane 
The SEM and TEM images of perfluorobutane droplets were not able to confirm 
encapsulation of liquid PFB into a lipid membrane. However, further stabilization with 
62 
another substance, such as glycerol, prolonged the lifetime of PFB droplets prior to ADV, 
which confirmed the stabilization of PFB droplets. 
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6. FUTURE STUDIES 
While the ultimate goal is to design a probubble that will begin as a droplet and 
vaporize into a microbubble using ultrasound, some details are still necessary to 
investigate. Some of these details include optimization of various steps in the process: 
A. One of the main methods that need to be investigated is the ability to obtain more 
uniform droplets. There are a number of parameters that can affect the distribution of 
droplets after homogenization, including the lipid composition, lipid concentration, 
perfluorocarbon concentration, type of membrane used during homogenization, 
number of passes through membrane, amount of pressure during homogenization, and 
rate of extrusion. The variation of membrane concentration to perfluorocarbon 
concentration has been investigated before (Gao, et al., 2008) but with biodegradable 
block copolymers. To eliminate the potential for human error during extrusion, 
Avestin has a pneumatic actuator (Ottawa, Canada) that is capable of performing the 
extrusion semi-automatically thereby controlling the amount of shear stress imposed 
upon the formation of droplets and existing droplets. However, a uniform sample of 
droplets greater than 200 nm may not be possible to fabricate via membrane 
extrusion. This is important because we want to know the initial nonvisible droplet 
size that would correspond to its final visible bubble. With the exception of other 
researchers (Lo, et al., 2007 and Giesecke and Hynynen 2003) who use a similar 
device to the Avanti Mini-Extruder (Liposofast), it appears that other groups obtain 
their uniform droplets via emulsification through a microfluidizer (Fan, et al., 2006 
and Schad and Hynynen 2010) or simple sonication in a water bath (Rapoport, et al., 
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2009). The potential problem with testing another device is the required capability of 
investigating lower boiling perfluorocarbons. 
B. Further investigation of stabilization of PFB droplets remains necessary to determine 
the best encapsulating method that would allow for lower Mis to be used to cavitate 
droplets. Even though glycerol provided enough stability for PFB droplets to perform 
ADV tests, it was impossible to monitor the size of the droplets using particle size 
analysis because samples were too polydisperse. Therefore, another stabilizer such as 
layer-by-layer assembly (Borden, et al., 2007) could be applied where shells of 
charged polymers "wrap" around the shells of the lipid membranes. The current 
membrane contains a polyethylene glycol tail that is pointed away from the droplet 
core and is slightly negatively charged. This negative charge can be a potential linker 
for a number of items including oppositely charged polymers, proteins, and 
monoclonal antibodies. Also, it may be possible to visualize smaller bubbles because 
the charges can be labeled with fluorescent dyes or other markers. Thus, the 
limitation for experimentation is the ability to visualize such small droplets, which 
should be tackled in future studies. 
Another potential method to investigate for stabilizing lower boiling 
perfluorocarbon droplets would be a mixture of perfluorocarbons. This had been 
done briefly with varying ratios of 2H,3H-perfluoropentane (BP = 55°C, Chemical 
Book 2008a) to perfluoropentane where an increase in the ratio resulted in an increase 
in vaporization threshold (Kawabata, et al., 2005). 
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C. This research would be accelerated with an apparatus that can liquefy low-boiling 
perfluorocarbons or hydrofluorocarbons at a rate that would be convenient for droplet 
formulation. This apparatus should be able to take nearly any perfluorocarbon or 
hydrofluorocarbon that is vapor at room temperature and condense it into liquid form. 
The amount of liquid produced would be known and kept inside a capped and 
crimped glass vial stored at -20°C. While the vapor temperature theory (section 
1.7.2) suggests that perfluoropropane (boiling point= -36.7°C, Linstrom and Mallard 
2010) can be encapsulated in a membrane and have an increased vapor temperature of 
35°C, the perfluorocarbons used within this apparatus must not have a vapor 
temperature less than -36.7°C and no more than room temperature (23°C). 
Homogenization processes typically take about 10 minutes when all material (lipids, 
cryoprotectant, and perfluorocarbon) are ready; therefore, the perfluorocarbons must 
liquefy within 5-10 minutes prior to homogenization, and homogenizations must 
occur at -20°C. 
D. Other imaging techniques for identification of droplet sizes may need to be 
approached. There exists a gravity-driven microfluidic particle sorting device that is 
capable of separating perfluorocarbon droplets that are about 1 µm or greater in 
diameter (Huh, et al., 2007). Such a device could be used to identify submicron 
droplets via an oil-immersion technique using a basic upright microscope. However, 
sub-microchannels would need to be used in addition to microchannels to route and 
visualize the droplets. Because there will always be a population of various sizes of 
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droplets and not necessarily a uniform sample, this device could assist in producing a 
more uniform sample. 
E. Another method of viewing smaller droplets, or even bubbles, would be necessary in 
order to accurately confirm the theoretical calculations of bubble expansion before 
and during ADV. Smaller droplets must be investigated to facilitate extravasation 
into the extravascular space. One possible method would be to isolate one droplet by 
attaching an optical dye and a ligand to the membrane. There will be a corresponding 
receptor that recognizes the ligand in agarose gel. Viewing may be done via 
noncontact atomic force microscopy (AFM), which can be performed for wet 
samples. 
On a similar note, the phenomena of Ostwald ripening needs to be confirmed with 
instruments that have high optical resolution as well as possibly with fluorescent tags 
attached either to the lipid membranes or the internal core. Such an instrument could 
potentially be used to further confirm not only the presence of perfluorocarbon 
droplets but also true encapsulation of perfluorocarbon within a droplet even though a 
whole population of droplets may be within the field of view. A very small sample of 
droplets between 100 and 200 nm in diameter must be isolated and tagged to see if 
such aggregation and coalescence would occur. Along with a potential fluorescent 
tag on either the lipid membrane or the internal core, an oil immersion microscope 
with epi-fluorescence illumination could be used with a charge-coupled device (CCD) 
camera to capture the small droplets. The droplets would be isolated via filtration. 
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F. While the tested droplets were larger than 1 µm in diameter, it remains necessary to 
develop smaller droplets that can extravasate to the extravascular space. The 
requirements for extravasation of these droplets might be varying diameters, lipid 
compositions, and outer membrane components (PEG lengths, charges, and ligands). 
Potential imaging of PFB droplets and even other PFC droplets via MRI may be 
beneficial to further confirm extravasation. In addition, MRI may be used to detect 
migration of PFC droplets into cells. This has been demonstrated by detecting 
tluorine-19 {1 9F) in nanoemulsions as they migrated into T cells (Janjic, et al., 2008). 
Perfluorocarbon emulsions with 19F have also been detected in rodent mammary 
tumors (Fan, et al., 2006). It is also possible to detect 19F nanoparticles to quantify 
angiogenesis (Water, et al., 2008). However, these methods with 19F MRI can be 
modified to determine the extravasation of PFC droplets after washouts. 
G. Another test group could involve isolated 100-200 nm droplets with ligands bound to 
corresponding receptors in a sol-gel glass matrix (Narang, et al., 1993). Such a ligand 
could potentially be attached to the droplets and specific droplets could be monitored 
during ADV testing to determine if single droplets can indeed cavitate into 
microbubbles. All experiments should be done in undegassed and degassed solutions 
at 3 7°C and atmospheric pressure. The same ultrasonic parameters should be applied. 
H. Investigations of cell internalizations of droplets need to be performed to study 
receptor specificity and nonspecific endocytosis. Therefore, methods of attaching 
certain ligands should be investigated in addition to determine which ligands might be 
appropriate for this diagnostic and/or therapeutic tool. Most of the 19F studies 
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mentioned earlier targeted specific cells. For example, one group incorporated a 
peptide ligand that recognizes the Uv~3 integrin onto their 19F nanoparticles to detect 
potential angiogenesis pertinent to atherosclerosis or aortic valve stenosis (Waters, et 
al., 2008). In addition, another group incorporated biotin to the membranes of some 
PFC ultrasound contrast agents to detect thrombi through a biotin-avidin system 
(Lanza, et al., 1997). Although these examples are restricted to the vasculature, 
similar methodologies could be involved when attaching a ligand to the membrane of 
a droplet. 
I. Other ultrasonic parameters not related to the MI need to be further investigated 
because MI is not a useful factor in determining potential bioeffects (Forsberg, et al., 
2005). MI is only limited to the peak negative pressure and the center frequency. 
Other parameters include TI (acoustic output [W/cm2] and energy required to raise 
tissue temperature 1 °C), pulse length, and exposure time. In addition, if these 
parameters are known, boundaries can then be set and applied for future experiments. 
J. Various in vivo time points are necessary to note to determine how the probubble will 
function. For example, it is necessary to identify how long it will take for the 
probubble to accumulate within tumor cells, especially after physiological washout, 
as well as how long it will take for the probubble to be cleared out of the body. 
Therefore, small animal models with tumors can be used for these investigations 
along with the appropriate ultrasound equipment for probubble functionality and 
visual cues. 
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K. Certainly, the probubble could potentially be used for other biomedical applications 
not limited to detecting and intoxicating tumors. For example, it had been proposed 
to use such a device for tissue occlusion therapy to cauterize blood vessels near tumor 
sites in addition to correcting any phase aberrations (Kripfgans, et al., 2000). 
Microbubbles improve contrast and highlight delineations within the region of 
interest on the ultrasound image. Therefore, the probubble can generally be used with 
nearly any ultrasound application where it may be difficult to view certain 
characteristics whether they may be particular to certain organs or even cellular 
structures. 
APPENDIX A: SPREADSHEET OF PERFLUOROCARBON DROPLET 
CALCULATIONS 
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Table 1.3 contains the physical properties of the perfluorocarbons used in these 
experiments. Below are the results from an Excel spreadsheet indicating the calculations 
involved in determining the final bubble size from the initial droplet size. 
A I 
Droplet 
1 i Diameter (nm) 280 F"'d/2 
2 :Volume (nm,..3) 4.19E+t6 V = (4/3)pi(rA3) 
3 Volume (mL) 4.19E--1S mL""' Ul"21 nmAl 
4 
f G 
P(atm) 1 
Vbubble (L) = nRT/P 
. n (mol) ""' Vdro let*Liquid Density/MW 
R (L*atmlmol*K) 0.0821 
T(K) 3UU3 
Bubble diameter (nm)"' ((Vbubble(L)*1080mUL*(10,..21)nm11.11mL*3!4/pi)"(ll3))1'2 
8 Factor,.., Bubble diameter/Droplet Diameter 
9 
Liquid Molecular Bubble 
Boiling Density weight Vbubble Diameter 
10 PFC point(°C) ) mol) n(mol) (L) (nm) 
PFH 56.6 l.71 33& 2.t2E-17 5.40E-16 1010.1 
PFMP 49.2 l.6 316.04 2.l2E-17 5AOE-l6 HH0.3 
PFP 29 1.63 288 2.31£-17 6.04E-16 1048.6 
PFB -1.7 L594 238,03 2.81E-17 7.14E-16 1109.0 
---~--~ 
H 
i 
l 
l 
Facto 
5J)5 
5.05 
5.24 
5.55 
71 
APPENDIX B: CALCULATIONS FOR ESTIMATED VAPOR TEMPERATURES 
Equation 6 shows a modified version of the Antoine equation where the vapor 
temperature is a function of the droplet radius taking into account the Laplace pressure. 
B T = --------,----------,- - C 
A-loglO(patm +Pbody + 2;) 
The corresponding spreadsheet setup along with formulas is shown below. 
~ A ; I I C -D I ' f G H 
1 Patm (bar) I Pbody (bar) I d (nm) r (m) Substance T (K) T ("C) 
2 ·--l-.O--'l-3--'---+----'0 ...... 12,__--"-+---l---+---'-I00-----"-+--5-"E-0--"-8---f--P-erl1_u_o_rn_h_exru1_e-+-4-2_,_5,...,_21-1-l-52,._.06-"-I 
surface tension 
(NIM) 
51 
l02 5.JE-08 A 424.27 15U2 
104 5.2E-08 4Ji7362 423.35 150.20 
106 5.:38-08 B 422.46 149.31 
6 l08 5.4E-08 H 13329 421.59 148.44 
1 r= dll/(10A9) no 5.5E-08 C 420.74 147.59 
8 112 5.6E-08 -56.472 419.91 146.76 
9 T(K)=B/(A· H4 5.7E-08 419.10 145.95 
.... ,LOG(Patm+Pbody+a/r/1000*(10"-5).10))•1--l_l6_· -+-_5_.8_E_-0_8-+-1i_em__,,_1ve_:ra_t_ure__,_(K_,)'-+-4_18_.3_1-+-14_5_.l------16 
11 C U8 5.9E-08 256.43-447.!)8 417.54 144.39 
'fj ("C)'"" T(K)-273.15 
ii 
15 
19 
..... 
120 6E-08 416.79 143.64 
122 6.lE-08 416.05 14::t90 
124 6.2E-08 415.33 142.18 
126 6.3E-08 414.63 141.48 
128 6.4E-08 413.94 140.79 
BO 6.SE-08 413.26 140.H 
132 6.6E-08 
134 6.7E-08 
136 6.SE-08 
138 6.9E-08 
140 7E-08 
142 7JE-08 
144 7.2E-08 
146 7.3E-08 
148 7.4E-08 
!50 7.SE-08 
152 7.6E-08 
,:- A '7 '7l'.LflQ 
412.60 139.45 
411.96 138.81 
411.32 i38J7 
410.70 137.55 
410.09 136.94 
409.50 136.35 
408.91 135.76 
408.33 135.18 
407.77 134.62 
407.22 134.07 
406.67 133.52 
AtlA 1.1. l':\7 nn 
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.. <?: I J I K L M N 0 ....• , ..••.. 
1 Substance T(K) T{°C} Substance T(K) T(OC) 
2 Perfluoropentane 390.94914 117.79914 Perfluorohutane 351.80297 78.652966 
3 A 390Jl7403 116.92403 A 351.00824 77.858242 
4 4.38423 389.22154 ll6.07154 4.1425 351l23434 77.084338 
$ i B 388.39069 115.24069 B 349.48033 76.330335 
, .... 
1257.758 387.58053 U4.43053 982.586 348.74537 75.595367 
; C 386.79021 ll:3.64021 C 348.02863 74.878625 
-13.231 386.01889 112.86889 -33.624 347.32935 74.179347 
I'"~=•»••·· ., ; 
385.2658 112.1158 346.64681 73.496814 
·~~ ~· , 
10 Te:nmerature fKl I 384.53022 111.38022 Temperature (K) 345.98035 72.830352 
11 300-421.8 383.81146 Jl0.66146 233.27-269.24 345.32932 72.179323 
12' 383.10886 109.95886 344.69312 71.543124 
l]l 382.42182 109.27182 344.07119 70.921188 381.74975 108.59975 343.46297 70.312975 
15; 381.0921 107.9421 342.86798 69.717977 
nmn 
380.44834 107.29834 342.28571 69.13571 
17 379.818 106.668 341.71572 68.565716 
m 379.20058 106.05058 341.15756 68.007561 
19 378.59565 105.44565 340.61083 67.460832 
... 
378.00278 104.85278 340.07514 66.925135 
21 377.42157 104.27157 339.5501 66.400098 
22 376.85162 103.70162 339.03536 65.885363 
'~••••~ A•>~ 
23 376.29258 Hl3J4258 338.53059 65.380593 
1·24" 375.74409 102.59409 338.03546 64.885462 
375.20582 102.05582 337.54966 64.399664 
'"""" .. ,. 
374.67744 IOI.52744 337.0729 63.922903 
12 374.15865 lOU)0865 336.6049 63.454891 ,, ..... 
28 373.64917 100.49917 336.14538 62.995378 
' "5Ci ii 11.'\ f,Q;ii)Q A'> ,AAf\lil! 
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I. T 
Substance T(K) T(OC) 
2 Perlluoropropane 307.72678 34.576778 
3 A 301.02085 33.810851 
4 4.08856 306.33348 33.183478 
5 B 305.66384 32.513836 
6 842.613 305.01116 31.861156 
C 304.37471 3L2247l2 
-30.023 303.75382 30.603824 
303.14785 29.997852 
Tem rature (I() 302.55619 29.406192 
193. 78~236.81 301.97828 28.828275 
301.41356 28.263564 
300.86155 27.71!551 
300.32176 27.171757 
299.79373 26.643725 
299.27703 26.127026 
298.77125 25.621251 
298.27601 25.126012 
297.79094 24.640941 
291.31569 24.165687 
296.84992 23.699916 
296.39331 23.243313 
295.94557 22.795573 
295.50641 22.356409 
295.07555 21.925546 
294.65272 21.502721 
294.23768 21.087682 
293.83019 20.680191 
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APPENDIX C: DAT A AND DA TA ANALYSIS FOR ST ABILITY 
Below are tables showing the z-averages of droplets for different storage 
temperatures over a period of 16-weeks. Z-averages of each sample were compared to 
baseline values at week O where the baseline values were taken as the "stable values" for 
error analysis. All samples were acquired using a 200 nm membrane filter. Asterisks 
indicate measurements were attempted but could not be measured due to technical 
reasons, and dashes indicate measurements were not attempted. Double dashes indicate 
mean was not calculated. 
Temperature = 4 °C Week 
Perfl uorocarbon Sample 0 2 4 8 12 16 
1 246.00 222.40 244.30 216.40 236.20 245.30 
PFH 2 218.80 200.60 202.30 199.20 193.10 200.40 
3 199.80 190.40 189.10 183.30 183.70 190.50 
mean 221.53 204.47 211.90 199.63 204.33 212.07 
4 240.10 231.20 230.60 230.70 229.00 244.30 
PFMP 5 153.20 153.20 151.60 157.70 151.40 156.70 
6 280.20 259.60 260.30 263.00 261.80 270.60 
mean 224.50 214.67 214.17 217.13 214.07 223.87 
7 156.40 157.70 156.70 155.40 153.70 156.70 
PFP 8 253.00 232.30 244.40 228.90 233.80 235.40 
9 215.00 206.90 200.40 201.20 211.00 215.90 
mean 208.13 198.97 200.50 195.17 199.50 202.67 
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Temperature= 23°C Week 
Per fluorocarbon Sample 0 2 4 8 12 16 
1 189.10 184.90 182.20 197.30 222.30 283.40 
PFH 2 249.70 235.20 166.00 205.30 195.70 162.70 
3 192.20 211.40 204.70 182.20 203.40 172.20 
mean 210.33 210.50 184.30 194.93 207.13 206.10 
4 341.50 204.50 201.70 170.40 196.70 185.20 
PFMP 5 219.40 394.80 373.50 323.40 * * 
6 219.40 200.90 194.00 190.60 209.40 191.70 
mean 260.10 266.73 256.40 228.13 -- --
7 255.80 209.20 234.00 214.50 269.20 289.20 
PFP 8 553.80 617.50 900.30 564.90 796.5.0 * 
9 172.70 188.60 238.70 184.40 332.10 * 
mean 327.43 338.43 457.67 321.27 465.93 --
Temperature = 40°C Week 
Perfluorocarbon Sample 0 2 4 8 12 16 
1 467.10 32.02 33.27 37.13 62.81 -
PFH 2 233.20 82.73 37.91 48.81 58.84 -
3 156.90 113.40 39.90 49.11 44.30 -
mean 285.73 76.05 37.03 45.02 55.32 -
4 191.70 106.40 44.19 40.05 42.41 -
PFMP 5 147.30 109.50 40.77 39.77 * -
6 164.10 107.70 39.59 49.85 79.64 -
mean 167.70 107.87 41.52 43.22 -- -
7 186.70 108.70 39.35 36.25 * -
PFP 8 203.80 156.60 133.90 131.10 57.85 -
9 138.70 41.83 41.07 34.12 * -
mean 176.40 102.38 71.44 67.16 -- -
76 
The stability of a droplet was determined based upon how well the sample of droplets 
remained the same size in terms of z-average and if their deviation was less than 10 
percent from the baseline z-average. Percent deviations were calculated for each 
individual sample then averaged for each corresponding perfluorocarbon and week. 
Bolded numbers in the following tables indicate average percent deviation greater than 10 
percent. In other words, the percent deviation was calculated as a standard error shown 
in the following equation. 
. . z - average - z - average . percent deviation = week n baseline X 100% Equation Cl 
z - average baseline 
The error bars were calculated as the standard deviations from the sample sets. 
A VERA GE PERCENT DEVIATION RELATIVE TO WEEK 0 
Temperature= 4°C Week 
PFC 2 4 8 12 16 
PFH -7.54 -4.53 -9.75 -7.93 -4.45 
PFMP -3.69 -4.03 -2.37 -4.12 0.20 
PFP -3.71 -3.33 -5.53 -3.73 -2.12 
Temperature = 23 °C Week 
PFC 2 4 8 12 16 
PFH 0.65 -10.22 -6.22 0.59 1.54 
PFMP 10.47 5.91 -5.28 - -
PFP 0.83 30.75 -2.46 47.12 -
Temperature= 40°C Week 
PFC 2 4 8 12 16 
PFH -61.80 -83.73 -79.94 -77.70 -
PFMP -34.84 -75.05 -73.91 - -
PFP -44.93 -61.20 -63.89 - -
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One-way analysis of variance (ANOVA) was performed via StatPlus for each 
sample set. Below are the results from the ANOVA tests performed. 
I 
4°C 
I Summary 
Groups Sample Sum Mean Variance 
size 
PFH 5 -34.2 -6.84 5.2986 
-PFMP 5 14.01 -2.802 3.30807 
-PFP 5 18.42 -3.684 1.49548 
I ANOVA I 
Source of Variation ss df MS F v-level F crit 
Between Groups 45.07284 2 22.53642 6.69256 0.01116 5.5163 
Within Groups 40.4086 12 3.36738 
Total 85.48144 14 
I 
23°c 
I Summary 
Grouvs Samvle size Sum Mean Variance 
PFH 5 -13.66 -2.732 27.23997 
PFMP 3 11.1 3.7 65.6787 
PFP 4 76.24 19.06 573.15433 
I ANOVA I 
Source of ss df MS F p-level F crit Variation 
Between 1,079.12832 2 539.56416 2.47787 0.1389 6.234 Groups 
Within 1,959.78028 9 217.75336 Groups 
Total 3,038.9086 11 
78 
40°c 
Summary 
Groups Sample size Sum Mean Variance 
PFH 4 -303.17 -75.7925 93.21143 
PFMP 3 -183.8 -61.26667 524.10143 
PFP 3 -170.02 -56.67333 105.23843 
ANOVA 
Source of ss df MS F p-level F crit Variation 
Between 710.83968 2 355.41984 1.61732 0.2646 7.20257 Groups 
Within 1,538.31401 7 219.75914 Groups 
Total 2,249.15369 9 
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APPENDIX D: SEM IMAGE OF PFP DROPLETS 
Figure Dl. Perfluoropentane droplet sample. a) SEM image and corresponding EDS of fluorine 
detected. Red circles in grey image indicate potential PFP droplets. b) Na and Cl EDS detected 
indicating potential salt crystal structures. c) EDS spectra obtained when analyzing 
perfluoropentane droplet sample. 
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